Merck & Co Inc reported better-than-expected quarterly results on Tuesday, with sales of consumer products and medicines for arthritis and HIV helping to offset the impact of generic competition on other drug sales.Merck, the No. 2 U.S. drugmaker, earned $2.03 billion, or 68 cents per share, in the second quarter. That compared with $906 million, or 30 cents per share, in the year-earlier period, when it took charges for acquisitions and restructuring.Excluding special items, Merck earned 85 cents per share. Analysts, on average, expected 81 cents, according to Thomson Reuters I/B/E/S.Global revenue slipped 1 percent to $10.93 billion, but exceeded expectations of $10.6 billion.
Merck & Co., Inc. (Merck), is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. Shares of MRK remained unchanged at $57.97. In the past year, the shares have traded as low as $44.62 and as high as $59.84. On average, 8884900 shares of MRK exchange hands on a given day and today's volume is recorded at 5082.
Thomson Reuters Corporation (Thomson Reuters) is a provider of information for the world?s businesses and professionals. Shares of TRI remained unchanged at $37.07. In the past year, the shares have traded as low as $32.87 and as high as $38.73. On average, 761364 shares of TRI exchange hands on a given day and today's volume is recorded at 0.
Thomson Reuters Corporation (Thomson Reuters) is a provider of information for the world?s businesses and professionals. Shares of TRI traded higher by 0.38% or $0.15/share to $40.03. In the past year, the shares have traded as low as $34.52 and as high as $42.10. On average, 574203 shares of TRI.TO exchange hands on a given day and today's volume is recorded at 395804.
Source
